Two Popular Pain Medications Could Soon Be Combined in One Tablet

One pill is about to replace two bottles in your medicine cabinet. On July 24, the Food and Drug Administration approved the first over-the-counter tablet combining Tylenol and naproxen sodium, the active ingredient in Aleve. Adults and children 12 and older will be able to grab a single dose for headaches, backaches, toothaches, menstrual cramps and minor arthritis pain. Kenvue, the company behind Tylenol, says the combination pill will land on store shelves at major retailers soon.

This article was created with the assistance of AI and reviewed by our editorial team for accuracy and clarity.

650 mg and 220 mg, Combined for the First Time

The approved dosage pairs 650 milligrams of acetaminophen with 220 milligrams of naproxen sodium in a single tablet. Acetaminophen and naproxen sodium rank among the most widely used pain relievers sold without a prescription in the United States, according to the FDA. Despite their popularity, no manufacturer had combined them into one product until now. The new option promises up to 12 hours of relief per dose, roughly double what either drug typically offers on its own.

Kenvue Says the Two Drugs Attack Pain Differently

The science behind the pairing comes down to speed and staying power. According to Michelle Bateson, who leads North America research and development at Kenvue, Tylenol dulls pain signals fast while naproxen sodium works on the inflammation causing that pain in the first place. Putting them in one tablet means patients get a quick knockdown followed by hours of sustained coverage, instead of timing two separate pills to overlap throughout the day.

Eight Clinical Trials Backed the Combination

Kenvue didn’t just theorize the pairing would work better. The company ran the combination through eight separate clinical studies before bringing it to the FDA. Bateson said the results showed “superior pain relief” when acetaminophen and naproxen sodium were taken together compared to either drug used alone. Those findings became the evidence base the FDA leaned on when it granted approval for the nonprescription version on July 24.

75% of Pain Sufferers Say Current Options Fall Short

The demand for something new was already there. A Kenvue survey of more than 6,200 people, conducted in March 2026, found that three out of every four people dealing with persistent pain were dissatisfied with the relief options available to them. That gap in the market is part of what the company points to as the reason for developing a fixed-dose combination rather than leaving consumers to juggle two separate bottles.

The FDA Ties the Approval to Trump’s Healthcare Push

This approval didn’t happen in isolation. In its announcement, the FDA said the decision aligns with President Trump’s healthcare initiative aimed at expanding access to verified safe drugs without a prescription. The FDA’s official approval notice frames the Tylenol-naproxen combination as an example of that broader effort. Whether that framing shapes how future OTC drugs reach the market remains to be seen.

Trump Once Urged Pregnant Women to Avoid Tylenol Entirely

The president’s relationship with Tylenol hasn’t always been this friendly. In 2025, Trump and top health officials urged pregnant women to stop taking the drug, pointing to an unproven link between acetaminophen and rising autism rates in children. Doctors and major medical groups pushed back, saying acetaminophen remains the preferred option for treating pain and fever during pregnancy. Kenvue has consistently maintained that Tylenol is safe when used as directed.

Texas Sued Kenvue Over Pregnancy Warnings

That controversy didn’t stay confined to public statements. Texas Attorney General Ken Paxton sued Kenvue and Johnson & Johnson in 2025, alleging the companies concealed risks to fetal development while marketing acetaminophen as safe for pregnant women. The lawsuit claims the companies ignored scientific concerns raised in a 2021 consensus statement signed by dozens of researchers. Kenvue has denied the allegations and says it stands behind decades of safety data.

An Appeals Court Just Revived 500 More Lawsuits

The legal pressure kept building. A federal appeals court ruled this month that a lower court wrongly excluded expert testimony in more than 500 private lawsuits accusing Kenvue of failing to warn pregnant women about acetaminophen’s alleged risks. The 2nd U.S. Circuit Court of Appeals sent the cases back for further proceedings, though the judges stressed they weren’t ruling on whether acetaminophen actually causes autism or ADHD.

A New Product Arrives Amid Old Questions

Tylenol with Naproxen represents a genuine advance in how millions of Americans might manage everyday pain, backed by eight clinical trials and a straightforward pitch: one pill, twelve hours, no opioids involved. But it’s launching into a moment when Kenvue is simultaneously fighting off hundreds of lawsuits and a state attorney general over claims tied to the same core ingredient. The science on the pill works. The politics around the brand remain unsettled.